As part of the partnership, Calibrant will identify protein networks and novel therapeutic targets involved in the progression of the most common and aggressive primary brain cancer, glioblastoma multiforme (GBM).
Brian Balgley, chief technology officer of Calibrant, said: “Our collaboration represents another important cancer drug program for Calibrant. The study reflects Calibrant’s ability to apply the gemini platform to targeted discovery from microdissected cell populations for the effective identification of disease-relevant pathways and drug targets.”